Oralead Pharma Ltd.

Based in Shenzhen, China and founded in 2022, Oralead Pharma Ltd. develops oral delivery technologies for large-molecule biopharmaceuticals. The company focuses on oral drug absorption mechanisms and formulation processes, supported by founders with backgrounds in gastrointestinal physiology and pharmacokinetics. The company has established a laboratory and co-created an R&D center with Innosmd and the Research Institute of Shenzhen Tsinghua University.

Its work includes the development of Macoral technology and multiple oral peptide pipelines. In January 2024, the company closed a pre-Series A funding round. The company works with biopharmaceutical developers to provide oral biologics delivery technologies and formulation processes. Its offerings include the Macoral oral large-molecule delivery platform, Simgut in-vitro absorption evaluation technology and several oral peptide drug candidates.

The company collaborates with research institutions and R&D teams to support product development. The company’s revenue is generated through research collaborations, technology licensing agreements and development partnerships related to its oral drug delivery platforms and peptide formulation technologies. The company plans to further develop its oral GLP-1 pipeline and expand its technology platforms for oral biologics delivery.